Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing for the exits Wednesday.
- Home |
- After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
- March 25, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
